Revised central nervous system neuropenetrationeffectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia

Antiviral Therapy

Volumn 18, Issue 2, 2013, Pages 153-160

  Ciccarelli, Nicoletta ^a   Fabbiani, Massimiliano ^a   Colaigli, Manuela ^a   Trecarichi, Enrico Maria ^a   Silveri, Maria Caterina ^a   Cauda, Roberto ^a   Murri, Rita ^a   De Luca, Andrea ^b   Di Giambenedetto, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG ABUSE; EDUCATIONAL STATUS; ETHNICITY; FEMALE; GENE DOSAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; ORIGINAL VERSION CENTRAL NERVOUS SYSTEM NEUROPENETRATION EFFECTIVENESS SCORE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVISED VERSION CENTRAL NERVOUS SYSTEM NEUROPENETRATION EFFECTIVENESS SCORE; RISK REDUCTION; SCORING SYSTEM; SELF REPORT; SEX DIFFERENCE; STROOP TEST; TASK PERFORMANCE; VIREMIA; VISUAL ANALOG SCALE; WORD RECOGNITION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS; TREATMENT OUTCOME; VIREMIA;

EID: 84875657273     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2560     Document Type: Article

References (37)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeiciency virus infection. N Engl J Med 1998; 338:853-860.
2. Antinori A, Arendt G, Becker JT, et al. Update research for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799.
3. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
4. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
5. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73:342-348.
6. Ferrando SJ, Rabkin JG, Van Gorp WG, et al. Longitudinal improvement in psychomotor processing is associated with potent antiretroviral therapy in HIV infection. J Neuropsychiatry Clin Neurosci 2003; 15:208-214.
7. Brew BJ, Crowe SM, Landay A, et al. Neurodegeneration and aging in the HAART era. J Neuroimmune Pharmacol 2009; 4:163-174.
8. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63:822-827.
9. Deeks SG. Immune dysfunction, inlammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17:118-123.
10. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10:81-86.
11. Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated to lower cognitive performance in HIV-infected patients. HIV Med 2012; doi: 10.1111/j.1468-1293.2012.01044.x
12. Ettenhofer ML, Hinkin CH, Castellon SA, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry 2009; 17:281-290.
13. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009; 19:169-185.
14. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal luid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
15. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal luid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819-1825.
16. Letendre SM, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetretion-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
17. Koopmans PP, Ellis R, Best BM, et al. Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med 2009; 67:206-211.
18. Cysique LA, Maruff P, Brew BJ. Variable beneit in neuropsychological function in HIV-infected HAARTtreated patients. Neurology 2006; 66:1447-1450.
19. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychological deicits despite long-term HAART in patients with HIV-related neurocognitive impairment. Prevalence and risk factors. J Acquir Immune Deic Syndr 2007; 45:174-182.
20. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug eficacy on HIV-associated neurocognitive disorders. J Acquir Immune Deic Syndr 2009; 52:56-63.
21. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal luid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
22. Letendre S, FitzSimons C, Ellis R, et al. Correlates of CSF viral loads in 1221 volunteers in the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 172.
23. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76:1403-1409.
24. Crum-Cianlone NF, Moore D, Letendre S, et al. An early diagnosed and treated HIV cohort shows low rates of neurocognitive impairment. 19th Conference on Retrovirus and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 500.
25. Antinori A, Lorenzini P, Giancola ML, et al. Antiretroviral CNS penetration effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma. 18th Conference on Retrovirus and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 426.
26. Murri R, Cingolani A, De Luca A, et al. Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. J Acquir Immune Deic Syndr 2010; 55:411-412.
27. Capitani E, Laiacona M. Composite neuropsychological batteries and demographic correction: standardization based on equivalent scores, with a review of published data. J Clin Exp Neuropsychol 1997; 19:795-809.
28. Yilmaz A, Gisslén M, Spudich S, et al. Raltegravir cerebrospinal luid concentrations in HIV-1 infection. PLoS ONE 2009; 4:e6877.
29. Yilmaz A, Izadkhashti A, Price RW, et al. Darunavir concentrations in cerebrospinal luid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25:457-461.
30. Yilmaz A, Watson V, Else L, et al. Cerebrospinal luid maraviroc concentrations in HIV-1 infected patients. AIDS 2009; 23:2537-2540.
31. Woods SP, Moore DJ, Weber E, et al. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009; 19:152-168.
32. Garvey L, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuroasymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 2011; 12:333-338.
33. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011; 76:693-700.
34. Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med 2009; 32:389-405.
35. Andrade AS, McGruder HF, Wu AW, et al. Programmable prompting device improves adherence to highly active antiretroviral therapy inHIV-infected subjects with memory impairment. Clin Infect Dis 2005; 41:875-882.
36. Wright MJ, Woo E, Foley J, et al. Antiretroviral adherence and the nature of HIV-associated verbal memory impairment. J Neuropsychiatry Clin Neurosci 2011; 23:324-331.
37. McManus H, Li PC, Nolan D, et al. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults? HIV Med 2011; 12:610-619.